FDA Policy on Unapproved Drug Products: Past,Present,and Future

Abstract

Spanish

French

OBJECTIVE

To review the history of drug regulation by the Food and Drug Administration (FDA) as it relates to unapproved drugs and FDA policy, along with the FDA's efforts to avoid future incidents by amending and enforcing those policies that are already in place.

DATA SOURCES

Data from FDA history documents, FDA guidances, Code of Federal Regulations Title 21, and presentations by the FDA's Office of Compliance were gathered.

STUDY SELECTION AND DATA EXTRACTION

All information identified from the data sources was evaluated, and all information deemed relevant was included for this review.

DATA SYNTHESIS

Contrary to popular belief, there are drugs on the market that have not been evaluated for safety or efficacy by the FDA. For almost a century, the FDA has taken action against public health threats posed by unapproved drug products, and today's drugs and vaccines are required to demonstrate both safety and efficacy prior to marketing. The FDA has taken great strides to ensure the welfare of Americans by reacting to disasters that have occurred in the past and being proactive by setting regulations that will prevent such catastrophes from occurring in the future.

CONCLUSIONS

The FDA recognizes that drug regulation is an ongoing process and that, although we have come a long way, there is still much to be done.

Keywords

Food and Drug Administration compliance Drug Efficacy Study Implementation

Get full access to this article

View all access options for this article.

References

1. Swann

. The history of drug regulation in the United States (exhibit). Rockville, MD: Food and Drug Administration History Office.

2. Less than effective (LTE) and identical, related and similar (IRS) drugs. Centers for Medicaid and Medicare Services. www.cms.hhs.gov/medicaid/drugs/drug11.asp (accessed 2004 Sept 3).

3. Marketed unapproved drugs—Compliance Policy Guide [draft guidance]. FDA/CDER; 2003 Oct 15. www.fda.gov/cder/guidance/5704dft.pdf (accessed 2004 Sept 3).

4. Temple

. DESI: design history (presentation). Rockville, MD: Food and Drug Administration, October 22, 2003.

5. Office of the Federal Register. 21CFR, part 314.200(e)(5). Washington, DC: US Government Printing Office, 2004. www.access.gpo.gov/cgi-bin/cfrassemble.cgi?title=200321 (accessed 2004 Sept 3).

6. Horowitz

. DESI: current status and unapproved drugs (presentation). Rockville, MD: Food and Drug Administration, October 22, 2003.

7. Lewis

, Castle

. Grandfathered drugs of 1938. Am Pharm 1978; 18: 36–9.

8. Micromedex, Inc. approved drug products and legal requirements. USPDI Volume III. Listing of “Pre-1938” Products. Englewood, CO: World Color Book Services:

9. Read

. DESI: brief legal history (presentation). Rockville, MD: Food and Drug Administration, October 22, 2003.

10.

10. Questions and answers on the Unapproved Drug Compliance Policy Guide: FDA/CDER, 2003 Oct 17. www.fda.gov/cder/compliance/ cpg_qanda.htm (accessed 2004 Sept 3).

11.

11. Marketed Unapproved Drugs—Compliance Policy Guide. www.fda.gov/cder/guidance/5704dft.pdf (accessed 2004 Sept 3).